Analysts Set Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Price Target at $42.60

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have been assigned a consensus recommendation of “Moderate Buy” from the five research firms that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $42.60.

Several equities analysts have issued reports on the company. HC Wainwright boosted their target price on Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, September 5th. Piper Sandler reissued a “neutral” rating and issued a $37.00 target price on shares of Collegium Pharmaceutical in a report on Friday, October 11th. Finally, StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 23rd.

Institutional Investors Weigh In On Collegium Pharmaceutical

A number of hedge funds have recently bought and sold shares of the business. nVerses Capital LLC increased its holdings in Collegium Pharmaceutical by 1,600.0% in the second quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock valued at $55,000 after buying an additional 1,600 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Collegium Pharmaceutical by 124.5% during the 3rd quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock valued at $55,000 after acquiring an additional 792 shares in the last quarter. CWM LLC lifted its stake in Collegium Pharmaceutical by 97.5% during the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock worth $58,000 after purchasing an additional 736 shares during the last quarter. TD Private Client Wealth LLC boosted its holdings in Collegium Pharmaceutical by 39.5% in the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock worth $66,000 after purchasing an additional 483 shares during the period. Finally, Virtus Fund Advisers LLC bought a new stake in Collegium Pharmaceutical during the third quarter valued at $72,000.

Collegium Pharmaceutical Trading Down 2.4 %

Shares of NASDAQ COLL opened at $29.70 on Thursday. The business has a fifty day moving average price of $32.48 and a 200 day moving average price of $34.30. Collegium Pharmaceutical has a 1-year low of $28.97 and a 1-year high of $42.29. The stock has a market capitalization of $957.83 million, a P/E ratio of 12.80 and a beta of 0.80. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.